Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_assertion description "[In conclusion, sulindac and its metabolites synergistically increase the anticancer effects of ?-lapachone primarily by increasing NQO1 activity and expression, and these two drugs may provide a novel combination therapy for lung cancers.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_assertion evidence source_evidence_literature NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_assertion SIO_000772 24505400 NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_assertion wasDerivedFrom befree-20150227 NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_assertion wasGeneratedBy ECO_0000203 NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.
- befree-20150227 importedOn "2015-02-27" NP354080.RAUx2qxXib2vCCW0Zn-mei3Wl_PxaoRvRvUdIt4KhB41E130_provenance.